Diligence memo · auto-generated · as of July 2, 2026
Trxade Group, Inc.
Trxade Group, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Trxade Group, Inc. operates in Pharmaceuticals, based in COMMACK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Trxade Group, Inc. has raised $74M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $65M on 2014-01-08.
Most recent recorded round closed around 2025-07-18.
Valuation (modeled)modeled
Provath models Trxade Group, Inc. at approximately $10M (range $5.6M–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.07× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 11 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 18% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.